SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gehrau R, Maluf D, Archer K, Descalzi V, Dumur C, Villamil F, Mas V. Long-term histological severity of HCV recurrence according to microRNA profiles obtained early after liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S138.
  • 2
    Mas V, Maluf D, Archer KJ, Potter A, Suh J, Gehrau R, et al. Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation. Liver Transpl 2011; 17: 824-835.
  • 3
    Gehrau R, Maluf D, Archer K, Stravitz R, Suh J, Le N, Mas V. Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients. Mol Med 2011; 17: 824-833.
  • 4
    Nadig SN, Arcerito M, Lee DD, Punch JD, Pelletier SJ. Quantifying hepatitis C viral (HCV) load in HCV-positive liver transplant recipients: influence of steroid therapy [abstract]. Liver Transpl 2012; 18( suppl 1): S125.
  • 5
    Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17: 1394-1403.
  • 6
    Andreani P, Zen Y, Maggi U, Valente R, Jassem W, Suddle A, et al. Outcome of donation after cardiac death liver transplantation for HCV [abstract]. Liver Transpl 2012; 18( suppl 1): S111.
  • 7
    Hernandez-Alejandro R, Croome KP, Quan D, Mawardi M, Chandok N, Dale C, et al. Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts. Transplantation 2011; 92: 686-689.
  • 8
    Taner CB, Bulatao IG, Keaveny AP, Willingham DL, Pungpapong S, Perry DK, et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl 2011; 17: 641-649.
  • 9
    Tao R, Ruppert K, Cruz RJ Jr, Malik SM, Shaikh O, Ahmad J, et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transpl 2010; 16: 1288-1295.
  • 10
    Saliba F, De Simone P, De Carlis L, Metselaar HJ, Beckebaum S, Jonas S, et al; for The H2304 Study Group. Everolimus with reduced tacrolimus exposure versus standard tacrolimus in hepatitis C virus positive de novo liver transplant recipients [abstract]. Liver Transpl 2012; 18( suppl 1): S98.
  • 11
    Rompianesi G, Montalti R, Di Benedetto F, Cautero N, De Ruvo N, Ballarin R, et al. Impact of everolimus monotherapy on HCV recurrence in liver transplant recipients: results of a randomized trial [abstract]. Liver Transpl 2012; 18( suppl 1): S98.
  • 12
    Villamil F, Gadano A, Zingale F, Perez R, Gil O, Yantorno S, et al.; for REVERT Study Group. Effect of everolimus on fibrosis progression in liver transplant patients with recurrent hepatitis C—results from the REVERT study [abstract]. Liver Transpl 2012; 18( suppl 1): S98.
  • 13
    McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387.
  • 14
    Asthana S, Toso C, Meeberg G, Bigam DL, Mason A, Shapiro J, Kneteman NM. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011; 25: 28-34.
  • 15
    Flemming JA, Zipperstein J, Peters MG, Roberts JP, Terrault NA. Histologic response to antiviral therapy in liver transplant recipients with hepatitis C confers a survival benefit in patients without a sustained virologic response [abstract]. Liver Transpl 2012; 18( suppl 1): S99.
  • 16
    Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al.; for HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-2441.
  • 17
    Aguilera V, Rubin A, Garcia M, San Juan F, López-Andujar R, Ortiz C, et al. Improved outcome after anti-HCV therapy is less marked when therapy is started at advanced stages of fibrosis [abstract]. Liver Transpl 2012; 18( suppl 1): S130.
  • 18
    Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738-746.
  • 19
    Berenguer M, Aguilera V, Rubín A, Ortíz C, Jimenez M, Prieto M. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol 2012; 56: 1310-1316.
  • 20
    Campos-Varela I, Esteban JI, Bilbao I, Allende H, Rodríguez-Frías F, Charco R, et al. Treatment with peg-interferon and ribavirin during early acute phase of the hepatitis C recurrence vs late hepatitis C recurrence after liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S137.
  • 21
    Tamura S, Sugawara Y, Yamashiki NA, Nojiri K, Kaneko J, Aoki T, et al. Pre-emptive antiviral therapy for hepatitis C in living donor liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S130.
  • 22
    Shin HJ, de Oliveira Pereira A, Safdar A, Tobias H, Gelb B, Morgan G, et al. Initial experience of telaprevir for recurrent hepatitis C in post liver transplant patients [abstract]. Liver Transpl 2012; 18( suppl 1): S130.
  • 23
    McCashland TM, Olivera-Martinez MA, Garcia-Saenz de Sicilia M, Mukherjee S, Rochling FA, Schafer DF, Sorrell MF. Early experience with triple drug therapy (telaprevir, pegylated interferon α2A and ribavirin) in patients on cyclosporine A for hepatitis C recurrence after liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S99.
  • 24
    Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux PG, Si-Ahmed SN, et al. A first multicentric experience of protease inhibitors for severe hepatitis C recurrence after liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S84.
  • 25
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
  • 26
    McLarnon A. Liver transplantation: boceprevir increases levels of ciclosporin and tacrolimus. Nat Rev Gastroenterol Hepatol 2012; 9: 366.
  • 27
    Fung J, Chan SC, Cheung CK, Chok KS, Sharr W, Chan AC, et al. Entecavir versus lamivudine prophylaxis without hepatitis B immune globulin after liver transplantation for chronic hepatitis B [abstract]. Liver Transpl 2012; 18( suppl 1): S124.
  • 28
    Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al.; for Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-360.
  • 29
    Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14: 479-487.
  • 30
    Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219.
  • 31
    Strignano P, Fagiuoli S, Lanza AG, Lauterio A, Conte G, Scuderi E, Carrai P. Subcutaneous anti-hepatitis B immunoglobulins (Zutectra™) after liver transplantation: an interim analysis of a multicenter, prospective, single-arm study [abstract]. Liver Transpl 2012; 18( suppl 1): S126.
  • 32
    Volpes R, Galatioto L, Vizzini G, Gridelli B. “Early” conversion to subcutaneous (SC) human HBV immunoglobulins (HBIg) is safe and effective in preventing HBV recurrence after liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S126.
  • 33
    Yahyazadeh A, Beckebaum S, Cicinnati V, Klein C, Paul A, Pascher A, Neuhaus R. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int 2011; 24: 441-450.
  • 34
    Singham J, Greanya ED, Lau K, Erb SR, Partovi N, Yoshida EM. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol 2010; 9: 166-171.
  • 35
    Teperman L; for ELAD VTI206 Clinical Development Team. A phase 2b study of safety & efficacy of a human cell-based biological liver support system (ELAD®) in subjects with acute-on-chronic hepatitis (AOCH) due either to acute alcoholic hepatitis or acute decompensation of cirrhosis [abstract]. Liver Transpl 2012; 18( suppl 1): S82.
  • 36
    Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, et al.; for Sirolimus Liver Conversion Trial Study Group. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012; 12: 694-705.
  • 37
    Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
  • 38
    O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
  • 39
    Basu PP, Nair T, Jafri M, Krishnaswamy N, Pacana T, Rayapudi K, Brown R. Transdermal rivastigmine for treatment of encephalopathy in liver cirrhosis—a randomized placebo controlled trial (TREC trial) [abstract]. Liver Transpl 2012; 18( suppl 1): S137.
  • 40
    Salvalaggio P, Dias M, Afonso R, Ferraz-Neto BH. Dealing with sick liver transplant recipients: the relationship among the MELD score at transplantation, post-transplant complications and resource consumption [abstract]. Liver Transpl 2012; 18( suppl 1): S85.
  • 41
    Yassen AM, Reffat WM, Elmorshedi MA, Salah T, Sultan AM, Elshopari M, Elsadany M. Right ventricular end diastolic volume as a guide for fluid resuscitation compared to central venous pressure in living donor liver transplantation. A randomized controlled trial [abstract]. Liver Transpl 2012; 18( suppl 1): S109.
  • 42
    De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al.; for H2304 Study Group. Renal function with everolimus and reduced tacrolimus in de novo liver transplant recipients: 12 month results of the H2304 study [abstract]. Liver Transpl 2012; 18( suppl 1): S85.
  • 43
    Fischer L, De Simone P, Fung J, Nevens F, Metselaar HJ, Beckebaum S, et al.; for H2304 Study Group. Wound healing events and arterial complications with everolimus versus tacrolimus based regimens in de novo liver transplant recipients [abstract]. Liver Transpl 2012; 18( suppl 1): S87.
  • 44
    Schlitt HJ, Lehner F, Neuhaus P, Schmidt J, Becker T, Hack MA, et al. Preservation of renal function in liver transplant recipients with Certican-based vs CNI-based therapy: the PROTECT study [abstract]. Liver Transpl 2012; 18( suppl 1): S86.
  • 45
    Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, Heimbach JK. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
  • 46
    Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012; 18: 641-658.
  • 47
    Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
  • 48
    Kaneku H, O'Leary JG, Susskind BM, Jennings LW, Terasaki PI, Klintmalm GB. Induction therapy decreases the risk of rejection after liver transplantation in patients with preformed donor-specific HLA antibodies [abstract]. Liver Transpl 2012; 18( suppl 1): S86.
  • 49
    Waki K, Chan SC, Terasaki PI, Ozawa M, Yik K, Lo CM. Association of donor-specific HLA antibody with acute rejection in living donor liver transplantation: a possible evidence of humoral sensitization [abstract]. Liver Transpl 2012; 18( suppl 1): S89.
  • 50
    O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Klintmalm GB, Terasaki PI. De novo MHC class II antibody formation impairs graft and patient survival after liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S110.
  • 51
    Shaked A, Feng S, Punch J, Reyes J, Levitsky J, Klintmalm G, et al. Initial outcomes of ITN030ST: early post-liver transplant immunosuppression withdrawal [abstract]. Liver Transpl 2012; 18( suppl 1): S106.
  • 52
    Sebagh M, Samuel D, Antonini T, Coilly A, Degli Esposti D, Roche B, et al. 20-year protocol liver biopsies: invasive but useful for the management of liver recipients [abstract]. Liver Transpl 2012; 18( suppl 1): S81.
  • 53
    Uchida Y, Ohe H, Yoshizawa A, Ogawa K, Ogura Y, Fujimoto Y, et al. Is it possible to wean immunosuppression in pediatric liver transplantation? The problem of long-term management [Per Supplement Issue.]. Liver Transpl 2012; 18( suppl 1): S82.
  • 54
    Banff Working Group on Liver Allograft Pathology, Demetris A. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012; 18: 1154-1170.
  • 55
    Syn WK, Nightingale P, Gunson B, Hubscher SG, Neuberger JM. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007; 13: 984-989.
  • 56
    Mells G, Mann C, Hubscher S, Neuberger J. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl 2009; 15: 931-938.
  • 57
    Del Gaudio M, Cescon M, Ercolani G, Pellegrini S, Ravaioli M, Cucchetti A, et al. Hepatocellular carcinoma on cirrhosis: liver resection, liver transplantation or both surgical treatments? [abstract]. Liver Transpl 2012; 18( suppl 1): S111.
  • 58
    Cunningham SC, Tsai S, Marques HP, Mira P, Cameron A, Barroso E, et al. Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol 2009; 16: 1820-1831.
  • 59
    Belghiti J. Resection and liver transplantation for HCC. J Gastroenterol 2009; 44( suppl 19): 132-135.
  • 60
    Goldberg D, French B, Abt P, Feng S, Cameron A. Increasing disparity in waitlist mortality rates with increased MELD scores for candidates with versus without hepatocellular carcinoma [abstract]. Liver Transpl 2012; 18( suppl 1): S136.
  • 61
    Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012; 56: 149-156.
  • 62
    Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1643-1648.
  • 63
    Sengupta B, Siddiqi SA. Hepatocellular carcinoma: important biomarkers and their significance in molecular diagnostics and therapy. Curr Med Chem 2012; 19: 3722-3729.
  • 64
    Shitani M, Sasaki S, Akutsu N, Takagi H, Suzuki H, Nojima M, et al. Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma. Tumour Biol 2012; 33: 1307-1317.
  • 65
    Zhang G, Ha SA, Kim HK, Yoo J, Kim S, Lee YS, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study. Dis Markers 2012; 32: 265-271.
  • 66
    Abdalla MA, Haj-Ahmad Y. Promising candidate urinary microRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer 2012; 3: 19-31.
  • 67
    Qiao SS, Cui ZQ, Gong L, Han H, Chen PC, Guo LM, et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 2011; 58: 1718-1724.
  • 68
    Schröder PC, Segura V, Riezu JI, Sangro B, Mato JM, Prieto J, et al. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. Funct Integr Genomics 2011; 11: 419-429.
  • 69
    Gehrau R, Maluf DG, Archer KJ, Mas V. Accurate multigenic test for hepatocellular carcinoma surveillance in hepatitis C virus-positive cirrhotic patients [abstract]. Liver Transpl 2012; 18( suppl 1): S84.
  • 70
    Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 2012; 138: 153-161.
  • 71
    Ng KT, Man K, Wong N, Li CX, Chan SC, Lo CM. Acute phase circulating micoRNAs predict tumor recurrence and survivals of hepatocellular carcinoma patients after liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S124.
  • 72
    Menon K, Hakeem A, Heaton N. A systematic review and metaanalysis of recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma [abstract]. Liver Transpl 2012; 18( suppl 1): S105.
  • 73
    Foss A, Adam R, Dueland S. Liver transplantation for colorectal liver metastases: revisiting the concept. Transpl Int 2010; 23: 679-685.
  • 74
    Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int 2008; 21: 1107-1117.
  • 75
    Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, et al. Liver transplantation for non-resectable liver metastases from colorectal cancer [abstract]. Liver Transpl 2012; 18( suppl 1): S140.
  • 76
    Hagness M, Foss A, Line PD, Dueland S. Factors influencing survival after liver transplantation for colorectal liver metastases [abstract]. Liver Transpl 2012; 18( suppl 1): S140.
  • 77
    Gallegos-Orozco JF, Silva AM, Chang YH, Batheja MJ, Hansen KN, Lam-Himlin D, et al. Magnetic resonance elastography (MRE) can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation [abstract]. Liver Transpl 2012; 18( suppl 1): S111.
  • 78
    Song GW, Lee SG, Hwang S, Ahn CS, Kim KH, Moon DB, et al. Fifteen-year experience of adult living donor liver transplantations in single institution [abstract]. Liver Transpl 2012; 18( suppl 1): S89.
  • 79
    Chan SC, Lo CM, Chok KS, Sharr WW, Cheung TT, Tsang SH, et al. Modulation of graft vascular inflow guided by flowmetry and manometry in liver transplantation. Hepatobiliary Pancreat Dis Int 2011; 10: 649-656.
  • 80
    Ishizaki Y, Kawasaki S, Sugo H, Yoshimoto J, Fujiwara N, Imamura H. Left lobe adult-to-adult living donor liver transplantation: should portal inflow modulation be added? Liver Transpl 2012; 18: 305-314.
  • 81
    Di Domenico S, Andorno E, Varotti G, Valente U. Hepatic flow optimization in full right split liver transplantation. World J Gastrointest Surg 2011; 3: 110-112.
  • 82
    Sainz-Barriga M, Scudeller L, Costa MG, de Hemptinne B, Troisi RI. Lack of a correlation between portal vein flow and pressure: toward a shared interpretation of hemodynamic stress governing inflow modulation in liver transplantation. Liver Transpl 2011; 17: 836-848.
  • 83
    Troisi RI, De Wolf E, Colle I, Berrevoet F, Rogiers X, Sainz-Barriga M. Prospective randomized double blind placebo controled study on the effect of somatostatin Eumedica® on graft inflow modulation and I/R injury in liver transplantation: preliminary results [abstract]. Liver Transpl 2012; 18( suppl 1): S101.
  • 84
    Cabús SS, Calatayud D, Ferrer J, Pavel MC, Melchor J, Martí J, et al. Portacaval shunt blood flow during anhepatic phase adequately predicts portal vein flow at reperfusion during living donor liver transplantation. Clinical implications [abstract]. Liver Transpl 2012; 18( suppl 1): S90.
  • 85
    Kakodkar R, Singla P, Mohanka R, Rastogi A, Goja S, Balachandran P, et al. Accessory hepatic vein reconstruction in right lobe living donor liver transplantation: will near infra-red spectroscopy with indo-cyanine green set new paradigms? [abstract]. Liver Transpl 2012; 18( suppl 1): S90.
  • 86
    Herden U, Grabhorn E, Ganschow R, Nashan B, Fischer L. Comparison of left-lateral liver grafts from living versus deceased donation in pediatric liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S81.
  • 87
    Platto M, Pietrobattista A, Ong E, Perera T, Lloyd C, McKiernan PJ, et al. 223 consecutive liver transplants in children using a split graft: a single centre experience [abstract]. Liver Transpl 2012; 18( suppl 1): S82.
  • 88
    Hashimoto K, Quintini C, Aucejo F, Fujiki M, Diago T, Watson M, et al. Split liver transplantation using hemiliver grafts: a single US center experience in the MELD era [abstract]. Liver Transpl 2012; 18( suppl 1): S116.
  • 89
    Humar A, Beissel J, Crotteau S, Kandaswamy R, Lake J, Payne W. Whole liver versus split liver versus living donor in the adult recipient: an analysis of outcomes by graft type. Transplantation 2008; 85: 1420-1424.
  • 90
    Broering DC, Schulte am Esch J, Fischer L, Rogiers X. Split liver transplantation. HPB (Oxford) 2004; 6: 76-82.
  • 91
    Chan EY, Olson LC, Kisthard JA, Perkins JD, Bakthavatsalam R, Halldorson JB, et al. Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transpl 2008; 14: 604-610.
  • 92
    Hong JC, Yersiz H, Kositamongkol P, Xia VW, Kaldas FM, Petrowsky H, et al. Liver transplantation using organ donation after cardiac death: a clinical predictive index for graft failure-free survival. Arch Surg 2011; 146: 1017-1023.
  • 93
    Dutkowski P, Schadde E, Breitenstein S, Schlegel A, Oberkofler CE, Müllhaupt B, Clavien PA. Balance of risk in liver transplantation—how much graft steatosis is tolerated? [abstract]. Liver Transpl 2012; 18( suppl 1): S95.
  • 94
    Verhoeven CJ, Farid WRR, de Ruiter PEE, de Jonge J, Kwekkeboom J, Metselaar HJ, et al. MicroRNAs in preservation solution are more predictive of graft quality than their expression in liver tissue [abstract]. Liver Transpl 2012; 18( suppl 1): S116.
  • 95
    Minou AF, Shcherba AE, Dzyadzko AM, Rummo OO, Fedoruk AM, Slobodin YV, et al. Preconditioning with sevoflurane decreases the incidence of early allograft dysfunction in liver transplant recipients of steatotic grafts [abstract]. Liver Transpl 2012; 18( suppl 1): S83.
  • 96
    Elaffandi AH, Aboutaleb E, Scalera I, Bonney GK, Mergantal H, Isaac JI, et al. Increasing the donor pool; the consideration of pre-hospital cardiac arrest in DCD donation for liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S117.
  • 97
    Taner B, Bulatao IG, Perry DK, Sibulesky L, Willingham DL, Kramer DJ, Nguyen JH. Asystole to cross clamp duration is predictor of ischemic type biliary strictures in liver transplantation using DCD grafts [abstract]. Liver Transpl 2012; 18( suppl 1): S81.
  • 98
    DeOliveira ML, Jassem W, Valente R, Khorsandi SE, Santori G, Prachalias A, et al. Biliary complications after liver transplantation using grafts from donors after cardiac death: results from a matched control study in a single large volume center. Ann Surg 2011; 254: 716-722.
  • 99
    Taner CB, Bulatao IG, Willingham DL, Perry DK, Sibulesky L, Pungpapong S, et al. Events in procurement as risk factors for ischemic cholangiopathy in liver transplantation using donation after cardiac death donors. Liver Transpl 2012; 18: 100-111.
  • 100
    Jay CL, Lyuksemburg V, Ladner DP, Wang E, Caicedo JC, Holl JL, et al. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Ann Surg 2011; 253: 259-264.
  • 101
    Giesbrandt K, Bulatao IG, Paz-Fumagalli R, Taner CB. Radiologic characterization and clinical correlation of ischemic cholangiopathy in liver transplants using donation after cardiac death donors [abstract]. Liver Transpl 2012; 18( suppl 1): S84.
  • 102
    Aoyagi T, Dondero F, Gaujoux S, Sommacale D, Dokmak S, Francoz C, et al. Orthotopic liver transplantation using selected advanced age donors should become a routine [abstract]. Liver Transpl 2012; 18( suppl 1): S116.
  • 103
    Tanabe M, Kawachi S, Obara H, Shinoda M, Hibi T, Kitagawa Y, et al. Current progress in ABO-incompatible liver transplantation. Eur J Clin Invest 2010; 40: 943-949.
  • 104
    Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Harada N, et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. Transplantation 2009; 88: 303-307.
  • 105
    Rull R, Garcia Valdecasas JC, Grande L, Fuster J, Lacy AM, González FX, et al. Intrahepatic biliary lesions after orthotopic liver transplantation. Transpl Int 2001; 14: 129-134.
  • 106
    Chui AK, Ling J, McCaughan GW, Painter D, Shun A, Dorney SF, et al. ABO blood group incompatibility in liver transplantation: a single-centre experience. Aust N Z J Surg 1997; 67: 275-278.
  • 107
    Song GW, Lee SG, Hwang S, Ahn CS, Kim KH, Moon DB, et al. Three-year experience of ABO-incompatible adult living donor liver transplantation in single center: no immunological failure with consecutive 80 cases under rituximab prophylaxis [abstract]. Liver Transpl 2012; 18( suppl 1): S139.
  • 108
    Rauchfuss F, Bauschke A, Settmacher U. Waiting time, not donor-risk-index, is a major determinant for beneficial outcome after liver transplantation in high-MELD patients [abstract]. Liver Transpl 2012; 18( suppl 1): S134.
  • 109
    Oniscu GC, Akyol M, Martin K. Outcome of patients with a MELD ≥25, given regional priority for liver transplantation [abstract]. Liver Transpl 2012; 18( suppl 1): S135.
  • 110
    Dirchwolf M, Ruf A, Khoury M, Bisigniano L, Krogh DH, Cairo F, et al. Deceased liver donor selection in Argentina: filling the gap between supply and demand [abstract]. Liver Transpl 2012; 18( suppl 1): S135.